Avesthagen Pharma signs pact with Elpen Pharmaceuticals

Avesthagen Pharma AG (APAG) on November 19, 2013, announced that it has signed an agreement with Greece-based Elpen Pharmaceuticals for the distribution of the biosimilar – AVDESP - in seven EU and six non-EU territories.

edited-villoo

Dr Villoo Morawala Patell, chairperson, APAG

AVDESP is a biosimilar for Darbepoetin alfa Aranesp, which is used for treating anaemia resulting from chronic kidney disorders and cancer chemotherapy.

According to the company's press release, as per the agreement, the distribution will happen in the following countries, namely, Greece, Cyprus, Bulgaria, Romania, Croatia, Slovenia, Slovakia, Serbia, Bosnia, Former Yugoslav Republic of Macedonia (FYROM), Albania, Montenegro and Kosovo, with a collective population base of over 70 million.

"We are excited about this alliance as we start our marketing in some of the most interesting countries, which will give us an opportunity to know these markets and interact with its people. The company is committed to deliver affordable healthcare for humanity," said Dr Villoo Morawala Patell, chairperson, APAG.

APAG is currently engaged with many other opportunities for a number of its ‘biosimilars' and ‘biobetters'.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X